Oxford Biomedica (OXB) RNS Announcements

Add to Alert list
Date Time Source Announcement
09 Mar 2018 03:17 PM
RNS
PROPOSED PLACING TO RAISE APPROXIMATELY £20.5M
01 Mar 2018 09:33 AM
RNS
Total Voting Rights
28 Feb 2018 07:15 AM
RNS
Hardman & Co Res: BIVV deal establishes structure
23 Feb 2018 02:03 PM
RNS
Director/PDMR Shareholding
20 Feb 2018 02:12 PM
RNS
Holdings in Company
15 Feb 2018 07:00 AM
RNS
Bioverativ Collaboration and Licence Agreement
01 Feb 2018 11:28 AM
RNS
Total Voting Rights
23 Jan 2018 09:45 AM
RNS
£3 million Innovate UK grant
23 Jan 2018 09:30 AM
RNS
Director Dealings / Market Share Purchase
17 Jan 2018 07:00 AM
RNS
Kymriah receives Priority Review for adult DLBCL
09 Jan 2018 09:54 AM
RNS
BLOCK LISTING RETURN
03 Jan 2018 01:33 PM
RNS
Holding(s) in Company
02 Jan 2018 09:49 AM
RNS
Total Voting Rights
20 Dec 2017 11:22 AM
RNS
Director Dealings / Market Share Purchase
11 Dec 2017 07:08 AM
RNS
Primary analysis results from JULIET trial
01 Dec 2017 10:16 AM
RNS
Total Voting Rights
23 Nov 2017 11:29 AM
RNS
Director Dealings / Market Share Purchase
09 Nov 2017 07:00 AM
RNS
OXB to present at Jefferies Healthcare Conference
06 Nov 2017 12:06 PM
RNS
Holdings in Company
06 Nov 2017 07:37 AM
RNS
CTL019 MAA submission to the EMA
01 Nov 2017 09:19 AM
RNS
Total Voting Rights
31 Oct 2017 04:01 PM
RNS
Kymriah submitted to FDA for adults with r/r DLBCL
23 Oct 2017 11:27 AM
RNS
Director Dealings / Market Share Purchase
02 Oct 2017 11:21 AM
RNS
Total Voting Rights
26 Sep 2017 02:55 PM
RNS
Director Dealings / Market Share Purchase
26 Sep 2017 09:37 AM
RNS
Long Term Incentive Plan Option Grant
25 Sep 2017 03:05 PM
RNS
Block listing application
25 Sep 2017 09:46 AM
RNS
Cantor Fitzgerald Healthcare Conference 2017
22 Sep 2017 12:36 PM
RNS
Director Dealings
20 Sep 2017 03:25 PM
RNS
Holding(s) in Company
19 Sep 2017 08:58 AM
RNS
Director Dealings
15 Sep 2017 09:21 AM
RNS
Director/PDMR Shareholding
12 Sep 2017 07:15 AM
RNS
Hardman Research: New advanced therapies era
07 Sep 2017 10:11 AM
RNS
Holdings in Company
05 Sep 2017 11:45 AM
RNS
Director/PDMR Shareholding
05 Sep 2017 11:39 AM
RNS
Director/PDMR Shareholding
05 Sep 2017 07:00 AM
RNS
OXB to Present at Rodman & Renshaw Conference
01 Sep 2017 09:25 AM
RNS
Total Voting Rights
30 Aug 2017 04:34 PM
RNS
CTL019 receives FDA approval
29 Aug 2017 07:00 AM
RNS
Stuart Paynter starts as new CFO
24 Aug 2017 10:41 AM
RNS
Hardman Research: Ready for CTL019 approval
23 Aug 2017 10:31 AM
RNS
Director Dealings / Market Share Purchase
22 Aug 2017 10:35 AM
RNS
Director Dealings / Market Share Sale and Purchase
17 Aug 2017 07:00 AM
RNS
Interim Results
11 Aug 2017 07:00 AM
RNS
OXB announces Innovate UK £2m collaboration
07 Aug 2017 09:05 AM
RNS
Holding(s) in Company
07 Aug 2017 07:00 AM
RNS
MHRA Licence For Commercial Supply
01 Aug 2017 09:19 AM
RNS
Total Voting Rights
25 Jul 2017 07:00 AM
RNS
Notice of Interim Results
24 Jul 2017 10:10 AM
RNS
Director Dealings / Market Share Purchase

Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.

Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.

Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.

UK 100